Printer Friendly

ADVANCED TISSUE SCIENCES AND MEDISORB SIGN JOINT DEVELOPMENT AGREEMENT

ADVANCED TISSUE SCIENCES AND MEDISORB SIGN JOINT DEVELOPMENT AGREEMENT
 LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Advanced Tissue Sciences (NASDAQ-NMS: ATISA) and Medisorb Technologies International L.P., a Stolle-DuPont Company, today signed a joint development and exclusive supply agreement through which Medisorb will develop customized synthetic, bioabsorbable mesh expressly for Advanced Tissue Sciences' therapeutic tissue products. When developed, the new mesh will consist of woven strands that will act as a biodegradable framework for growing skin, cartilage, oral mucosa, bone marrow and liver tissue.
 Advanced Tissue Sciences is engaged in the growth of human tissue outside the body. The company is developing its proprietary three- dimensional cell culture system for potential therapeutic and laboratory applications.
 Medisorb Technologies International L.P. (MTI) is a world leader in the development of controlled release delivery systems (pharmaceuticals, peptides, vaccines) and bioabsorbable medical devices. MTI offers Food and Drug Administration-registered development and manufacturing facilities. The company also manufactures and markets Medisorb (R) and Vetisorb (R) lactide-glycolide polymers.
 -0- 2/3/92
 /CONTACT: Alana B. Wheeler of Advanced Tissue Sciences, 619-450-5714; or Charles T. White of Medisorb Technologies International, 513-489-7181/
 (ATISA) CO: Advanced Tissue Sciences Inc.; Medisorb Technologies International
 L.P. ST: California IN: MTC SU: JVN


KJ-CH -- SD002 -- 6178 02/03/92 12:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:210
Previous Article:SUN DISTRIBUTORS NET INCOME $3.2 MILLION IN FOURTH QUARTER
Next Article:94 PERCENT OF ENZO BIOCHEM DEBENTURES CONVERTED TO STOCK; ENZO GAINS $32.5 MILLION IN NET WORTH FROM $28.2 MILLION CONVERSION
Topics:


Related Articles
ADVANCED TISSUE SCIENCES ANNOUNCES LETTER OF INTENT TO ACQUIRE NEOMORPHICS INC.
ADVANCED TISSUE SCIENCES AND CELL GENESYS TO COLLABORATE IN DEVELOPING A UNIVERSAL 'FULL-THICKNESS' SKIN TRANSPLANT PRODUCT
ADVANCED TISSUE SCIENCES INC. REPORTS FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES AND ST. JUDE MEDICAL ANNOUNCE ALLIANCE TO PURSUE TISSUE ENGINEERED HEART VALVES
ST. JUDE MEDICAL, INC. AND ADVANCED TISSUE SCIENCES ANNOUNCE ALLIANCE TO PURSUE TISSUE ENGINEERED HEART VALVES
ADVANCED TISSUE SCIENCES AND SMITH & NEPHEW ANNOUNCE JOINT VENTURE TO DEVELOP TISSUE ENGINEERED CARTILAGE FOR ORTHOPEDIC APPLICATIONS
Advanced Tissue Sciences Announces Second Quarter Results
Advanced Tissue Sciences and Smith & Nephew Expand Dermagraft(R) Joint Venture
Advanced Tissue Sciences Announces Further Expansion of Dermagraft Joint Venture

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters